Dmitry Balyasny’s Marker Therapeutics MRKR Stock Holding History

Dmitry Balyasny’s Portfolio MRKR Stock Details MRKR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-7,319	Closed	-$580K	–	1428
2019 Q2	$580K	Buy	+7,319	New	+$435K	﹤0.01%	1196

Other funds holding MRKR

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Dmitry Balyasny's MRKR Position: Q3 2019 in Review

Dmitry Balyasny sold out of Marker Therapeutics (MRKR) in Q3 2019, closing a stake of 7,319 shares — an estimated $580K sold.

Dmitry Balyasny first reported a position in MRKR in Q2 2019 and held it in 1 quarter. The position peaked at $580K in Q2 2019. 73 funds tracked by Wall St. Rank hold MRKR as of Q3 2019.

Dmitry Balyasny reported no remaining Marker Therapeutics position as of Q3 2019 after selling out during the quarter.
Dmitry Balyasny sold 7,319 Marker Therapeutics shares in Q3 2019, an estimated $580K.
Dmitry Balyasny first reported a position in Marker Therapeutics in Q2 2019 and held it in 1 quarter.
Dmitry Balyasny's Marker Therapeutics position peaked at $580K in Q2 2019.
73 funds tracked by Wall St. Rank held Marker Therapeutics as of Q3 2019.

Based on Balyasny Asset Management's 13F filing for Q3 2019, filed 14 Nov 2019.